New Antigens Against Glioblastoma

Identification of New Antigens Against Glioblastoma

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05917821

Acronym

INAAG

Enrollment

120

Registered

2023-06-26

Start date

2023-08-01

Completion date

2027-09-30

Last updated

2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme

Brief summary

In this study the investigators will select and develop potential therapeutic monoclonal antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to test monoclonal antibodies specificity and target distribution, selection of glioblastoma specific functional monoclonal antibodies, identification of candidate targets.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* age \> 18 years; * Written informed consent

Exclusion criteria

* Not-availability of informed consent

Design outcomes

Primary

Measure	Time frame	Description
Validation of the tumour specificity of the identified monoclonal antibodies	4 years	Candidate monoclonal antibodies will be tested by immunohistochemistry (IHC) on sections of glioblastoma tissue and healthy counterpart.

Secondary

Measure	Time frame	Description
Generate the single chain Fab antibody fragments (scFv) and then develop the Chimeric Antigen Receptor (CAR) T cells	4 years	After defining a subset of potentially highly selective \ 7 monoclonal antibodies, together with the \ 6 that showed preliminary activity in cytotoxic tests (either alone or conjugated), the investigators will perform a thorough analysis of their specificity on a TMA platform. After establishing the staining conditions, the investigators will test multiple tumor and multiple normal TMAs

Outcome results